Ethris has entered a strategic partnership with Thermo Fisher Scientific to provide a completely integrated messenger ribonucleic acid (mRNA) solution to biopharmaceutical developers.
The partnership aims to accelerate the progression of candidate mRNA medicines from research to clinical proof-of-concept.
Go deeper with GlobalData
It will combine Ethris’ advanced technology platforms with Thermo Fisher’s good manufacturing practice-compliant manufacturing capabilities.
Ethris CEO Carsten Rudolph stated: “Thermo Fisher Scientific has a long-standing track record of supporting the development of advanced therapies.
“By combining our clinically validated mRNA platforms with Thermo Fisher’s manufacturing expertise, we are creating a powerful offering for biopharma partners. This collaboration addresses the increasing demand for scaleable, high-quality mRNA technologies and enables us to serve a broader set of collaborators worldwide.”
The collaboration will expand worldwide access to Ethris’ suite of mRNA technologies, including its stabilised non-immunogenic mRNA (SNIM RNA).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSNIM RNAs are non-immunogenic and can therefore be administered repeatedly, resulting in sustained production of proteins that are therapeutically active within the human body.
These platforms are designed for safe drug production while allowing scaleable manufacturing processes.
Ethris’ platform technologies have shown favourable results in Phase I trials for ETH47, a candidate targeting asthma exacerbations through nasal administration.
The trial data indicated dose-dependent protein production at the site without systemic bioavailability.
Thermo Fisher scientific large molecule drug substance vice-president and general manager Ben Castro stated: “Thermo Fisher is committed to supporting the rapid translation of breakthrough therapies into clinical application.
“By partnering with Ethris, we are expanding our services to include cutting-edge mRNA manufacturing, empowering our customers to bring life-changing treatments to patients faster and more efficiently.”
mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
